One-Year Progression of Diabetic Subclinical Macular Edema in Eyes with Mild Nonproliferative Diabetic Retinopathy: Location of the Increase in Retinal Thickness

2015 ◽  
Vol 54 (3) ◽  
pp. 118-123 ◽  
Author(s):  
Amparo Navea Tejerina ◽  
Stela Vujosevic ◽  
Monica Varano ◽  
Catherine Egan ◽  
Sobha Sivaprasad ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Retinal Thickness ◽  
Nonproliferative Diabetic Retinopathy ◽  
One Year

Efficacy of Intravitreal Triamcinolone after or Concomitant with Laser Photocoagulation in Nonproliferative Diabetic Retinopathy with Macular Edema

2009 ◽  
Vol 19 (4) ◽  
pp. 630-637 ◽  
Author(s):  
Erdinc Aydin ◽  
Helin Deniz Demir ◽  
Huseyin Yardim ◽  
Unal Erkorkmaz
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Laser Photocoagulation ◽  
Control Group ◽  
Clinical Effects ◽  
Intravitreal Triamcinolone ◽  
Nonproliferative Diabetic Retinopathy ◽  
Significant Difference ◽  
Group 3 ◽  
The Mean

Purpose To investigate the clinical effects and outcomes of intravitreal injection of 4 mg of triamcinolone acetonide (IVTA) after or concomitant with macular laser photocoagulation (MP) for clinically significant macular edema (CSME). Methods Forty-nine eyes of 49 patients with nonproliferative diabetic retinopathy and CSME were randomized into three groups. The eyes in the laser group (n=17), group 1, were subjected to MP 3 weeks after IVTA; the eyes in the IVTA group (n=13), group 2, were subjected to MP, concomitant with IVTA; the eyes in the control group (n=19), group 3, underwent only IVTA application. Visual acuity (VA), fundus fluorescein angiography, and photography were performed in each group. Results In the first group, the mean VA improved from 0.17±0.09 at baseline to 0.28±0.15 (p=0.114) and in the second group, deteriorated from 0.19±0.08 at baseline to 0.14±0.08 at the sixth month (p=0.141), respectively. In Group 3, the mean VA improved from 0.16±0.08 at baseline to 0.28±0.18 (p=0.118) at the end of the follow-up. When VA was compared between the control and study groups, significant difference was detected at the sixth month (p=0.038). Conclusions MP after IVTA improved VA, rather than MP concomitant with IVTA, and only IVTA application for CSME. MP after IVTA may reduce the recurrence of CSME and needs further investigations in a longer period.

Different Phenotypes of Mild Nonproliferative Diabetic Retinopathy with Different Risks for Development of Macular Edema (C-TRACER Study)

2017 ◽  
Vol 59 (2) ◽  
pp. 59-67 ◽  
Author(s):  
Luísa Ribeiro ◽  
Rajeev Pappuru ◽  
Conceição Lobo ◽  
Dalila Alves ◽  
José Cunha-Vaz
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Tracer Study ◽  
Nonproliferative Diabetic Retinopathy

Nonproliferative diabetic retinopathy and macular edema progression after phacoemulsification: Prospective study

2006 ◽  
Vol 32 (9) ◽  
pp. 1438-1444 ◽  
Author(s):  
Pedro Romero-Aroca ◽  
Juan Fernández-Ballart ◽  
Matias Almena-Garcia ◽  
Isabel Méndez-Marín ◽  
Merce Salvat-Serra ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Prospective Study ◽  
Macular Edema ◽  
Nonproliferative Diabetic Retinopathy

Analysis of the effectiveness of medical and laser treatment of patients with diabetic retinopathy

2012 ◽  
Vol 93 (4) ◽  
pp. 594-597
Author(s):  
V V Kuzovnikov ◽  
V A Nevmerzhitskaya ◽  
V I Lazarenko
Keyword(s):  
Diabetic Retinopathy ◽  
Laser Treatment ◽  
Standard Treatment ◽  
Central Field ◽  
Nonproliferative Diabetic Retinopathy ◽  
Field Of Vision ◽  
New Treatment ◽  
One Year ◽  
Positive Effect ◽  
Observation Period

Aim. To evaluate the effectiveness of traditional medical and laser treatment of nonproliferative and preproliferative diabetic retinopathy. Methods. Examined was a total of 80 eyes of 66 patients with nonproliferative and preproliferative diabetic retinopathy. In accordance with the stage of the disease and the type of treatment, all patients were divided into two groups. The first group consisted of 34 individuals (39 eyes) with nonproliferative diabetic retinopathy who received medical treatment, the second group - 32 individuals (41 eyes) with preproliferative diabetic retinopathy who received medical and laser treatment. The patients had visual acuity measurement, biomicroscopy, ophthalmoscopy, refractometry, perimetry, a study of the central field of vision, and rheoophthalmography performed before surgery, after surgery (at discharge), 10 days, 6 months and 1 year postoperatively. Results. The indices of visual functions, the hemodynamic and electrophysiological parameters have the same dynamics in the first and second groups throughout the observation period. In both groups a positive effect of the performed treatment was noted, which is almost entirely offset by 6-month post-treatment, and by one year after treatment a negative dynamic develops, which is associated with the progressive course of the disease. Conclusion. The lack of effectiveness of the standard treatment of nonproliferative and preproliferative diabetic retinopathy is the justification for a search for new treatment methods.

scholarly journals Effect of Hemodialysis on Retinal Thickness in Patients with Diabetic Retinopathy, with and without Macular Edema, Using Optical Coherence Tomography

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Nur Azem ◽  
Oriel Spierer ◽  
Meital Shaked ◽  
Meira Neudorfer
Keyword(s):  
Blood Pressure ◽  
Optical Coherence Tomography ◽  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Retinal Thickness ◽  
Optical Coherence ◽  
Before And After ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background.Effects of hemodialysis (HD) treatment on retinal thickness and macular edema are unclear.Objective.To evaluate changes in retinal thickness using optical coherence tomography (OCT) in end stage renal disease (ESRD) patients with diabetic retinopathy (DR), with and without diabetic macular edema (DME), undergoing HD.Methods.Nonrandomized prospective study. Forty eyes of DR patients with ESRD treated with HD were divided into two groups: patients with macular edema and patients without macular edema. Both eyes were analyzed. Patients underwent an ophthalmic examination including OCT measurements of retinal thickness, blood albumin and hemoglobin A1C levels, blood pressure, and body weight, 30 minutes before and after HD.Results.We found no significant effects of HD on retinal thickness among patients both with and without DME. The former showed a trend towards reduction in retinal thickness in foveal area following HD, while the latter showed an increase. There was no correlation between retinal thickness and mean blood pressure, weight, kinetic model value—Kt/V, glycemic hemoglobin, or albumin levels before and after HD.Conclusions.HD has no significant effect on retinal thickness among patients with or without DME. Further studies on larger cohorts and repeated OCT examinations are needed to confirm the preliminary findings in this study.

scholarly journals Effect of Adding Losartan to Bevacizumab for Treating Diabetic Macular Edema

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Fariba Ghassemi ◽  
Abdulrahim Amini ◽  
Masoud Yasemi ◽  
Amin Nabavi ◽  
Mohammadkarim Johari
Keyword(s):  
Blood Pressure ◽  
Visual Acuity ◽  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Glycosylated Hemoglobin ◽  
Macular Thickness ◽  
Central Macular Thickness ◽  
Nonproliferative Diabetic Retinopathy ◽  
Significant Difference

Introduction. Diabetic retinopathy is the most common cause of visual loss and blindness in the age group of 20 to 64 years. This study aimed to evaluate the efficacy of oral Losartan adjuvant therapy in combination with intravitreal injection of Bevacizumab in the treatment of diabetic macular edema. Methods. In this randomized clinical trial, 61 eyes of 47 patients with normal blood pressure and diabetic macular edema and nonproliferative diabetic retinopathy were studied. Patients were randomly divided into Losartan (n = 33) and control (n = 28) groups. All patients received 3–6 intravitreal injections of Bevacizumab over 6 months. General examination including blood pressure and glycosylated hemoglobin measurements were performed in all patients. Complete ophthalmologic examination and macular OCT were performed at the first, third, and sixth months of treatment in all patients. Results. The mean age of the patients studied was 57.1 ± 7.4 years and 37.7% of the patients were male. There was no significant difference between the two groups in terms of initial visual acuity, central macular thickness, and frequency of injections. There was no significant difference in visual acuity and central macular thickness between the two groups at the first, third, and sixth months of treatment. Age, frequency of injection, and initial macular thickness less than 450 microns were effective in patients’ final visual acuity. Conclusion. Short-term adjuvant treatment with Losartan in patients with diabetic macular edema and nonproliferative diabetic retinopathy has no greater effect than the standard treatment.

Early Photocoagulation for Diabetic Retinopathy

2020 ◽  
pp. 177-184
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Clinical Trial ◽  
Diabetic Retinopathy ◽  
High Risk ◽  
Macular Edema ◽  
Proliferative Retinopathy ◽  
Diabetic Patients ◽  
Nonproliferative Diabetic Retinopathy ◽  
Proliferative Stage ◽  
Focal Treatment ◽  
Photocoagulation Therapy

The Early Treatment Diabetic Retinopathy Study (ETDRS) was a randomized clinical trial involving nearly four thousand diabetic patients with early proliferative retinopathy, moderate to severe nonproliferative retinopathy, and/or diabetic macular edema in each eye. This paper (ETDRS report number 9) examined the question of when in the course of diabetic retinopathy it is most effective to initiate photocoagulation therapy. Based on the study findings, the authors recommended that panretinal scatter photocoagulation not be carried out in eyes with mild or moderate nonproliferative diabetic retinopathy; when retinopathy is more severe, however, panretinal scatter photocoagulation usually should not be delayed if the eye has reached the high-risk proliferative stage. Focal treatment should be considered for eyes with macular edema that involves or threatens the center of the macula, preferably before scatter photocoagulation for high-risk proliferative retinopathy becomes urgent.

Photocoagulation for Diabetic Macular Edema

2020 ◽  
pp. 169-176
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Laser Photocoagulation ◽  
Argon Laser ◽  
Diabetic Patients ◽  
Nonproliferative Diabetic Retinopathy ◽  
Argon Laser Photocoagulation ◽  
Clinically Significant Macular Edema ◽  
Clinically Significant

The Early Treatment Diabetic Retinopathy Study (ETDRS) was a randomized clinical trial involving nearly four thousand diabetic patients with early proliferative retinopathy, moderate to severe nonproliferative retinopathy, and/or diabetic macular edema in each eye. This paper (ETDRS report number 1) describes the findings in the subgroup of eyes in the ETDRS that were identified as having mild to moderate nonproliferative diabetic retinopathy and macular edema. The analysis showed that immediate focal argon laser photocoagulation of “clinically significant” diabetic macular edema substantially reduced the risk of visual loss, increased the chance of visual improvement, decreased the frequency of persistent macular edema, and caused only minor visual field losses. The authors recommended immediate focal argon laser photocoagulation for all eyes with clinically significant macular edema and mild or moderate nonproliferative diabetic retinopathy, regardless of the level of visual acuity.

scholarly journals Decreased Retinal Thickness in Type 1 Diabetic Children with Signs of Nonproliferative Diabetic Retinopathy

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
P. Ruiz-Ocaña ◽  
P. Espinoza Requena ◽  
A. Alonso-Ojembarrena ◽  
P. Alemany Márquez ◽  
S. Jiménez Carmona ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Metabolic Control ◽  
Retinal Thickness ◽  
Neurovascular Unit ◽  
Neuronal Loss ◽  
Control Group ◽  
Healthy Controls ◽  
Nonproliferative Diabetic Retinopathy ◽  
Poor Metabolic Control

The retina functions as a neurovascular unit. How early vascular alterations affect neuronal layers remains controversial; early vascular failure could lead to edema increasing retinal thicknesses, but alternatively neuronal loss could lead to reduced retinal thickness. Objective. To evaluate retinal thickness in a cohort of pediatric patients with type 1 diabetes mellitus (PwT1DM) and to analyze differences according to the presence or absence of nonproliferative diabetic retinopathy (NPDR), poor metabolic control, and diabetes duration. Patients and Methods. We performed retinographies and optical coherence tomography (OCT) (TOPCON 3D1000®) to PwT1DM followed at our center and healthy controls. Measurements of the control group served to calculate reference values. Results. 59 PwT1DM (age 12.51 ± 2.59) and 22 healthy controls (age 10.66 ± 2.51) volunteered. Only two PwT1DM, both adolescents with poor metabolic control, presented NPRD. Both showed decreased thicknesses and retinal volumes. The odds ratio of having decreased retinal thickness when signs of NPDR were present was 11.72 (95% IC 1.16–118.28; p=0.036). Conclusions. PwT1DM with NPDR have increased odds of decreased retinal thicknesses and volumes. Whether these changes are reversible by improving metabolic control or not remains to be elucidated.

Sign in / Sign up

Export Citation Format

Share Document